A
Alcista
Alcista · 25%TAK
$18.07
Precio del escenario
$19.670
+0.222 (+1.13%)Al cierre
Loading chart…
- Máximo
- 19.705
- Apertura
- 19.670
- Precio medio ponderado por volumen
- 19.65
- Volumen
- 2.83M
- Capitalización
- 40.51B
- Mínimo
- 19.561
- Importe
- 55.55M
- EV/EBITDA, TTM
- 3.05
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
Análisis de IA of Takeda Pharmaceutical Co Ltd (TAK)
ComprarTakeda Pharmaceutical Co Ltd (TAK) appears to be a good buy right now due to its current price of 18.73, which is above the 200-day simple moving average of 17.25, suggesting a bullish trend. Additionally, the stock has shown a strong year-to-date change of +19.91% and a one-year change of +36.52%, indicating solid performance. The RSI of 67.41 suggests that the stock is nearing overbought conditions but still has room for growth. The main risk is the negative net income reported in Q4 2026, which was -368.47 billion JPY, highlighting potential volatility in earnings.
Métricas de valoración
El PER previsto actual de Takeda Pharmaceutical Co Ltd (TAK) es 11.47, frente a su media de 5 años de 25.23.
Escenarios de precio de Alphio AI para TAK
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
5.010-15NewsfilterORZEYFUL Approved for Launch in Japan and China
- 9.009-30Newsfilter
Zasocitinib Shows Superiority in Psoriasis Treatment
- 9.009-22Newsfilter
Takeda Unveils New Data at ESMO Congress on Cancer Treatments
- 8.509-18Newsfilter
Takeda Awards $22.2 Million to 2026 Global CSR Partners
- 8.509-14Newsfilter
Takeda's Zasocitinib Receives FDA Priority Review for Psoriasis
Preguntas frecuentes sobre TAK, respondidas por Alphio AI
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies. It operates in the Healthcare sector.
Takeda Pharmaceutical Co Ltd (TAK) appears to be a good buy right now due to its current price of 18.73, which is above the 200-day simple moving average of 17.25, suggesting a bullish trend. Additionally, the stock has shown a strong year-to-date change of +19.91% and a one-year change of +36.52%, indicating solid performance. The RSI of 67.41 suggests that the stock is nearing overbought conditions but still has room for growth. The main risk is the negative net income reported in Q4 2026, which was -368.47 billion JPY, highlighting potential volatility in earnings.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.